Influence of multivalent nitrilotriacetic acid lipid-ligand affinity on the circulation half-life in mice of a liposome-attached His6-protein.
Metal chelation-ligand interactions, such as occur between nitrilotriacetic acid (NTA)-nickel and multihistidines, enable the noncovalent attachment of histidine-modified proteins to liposomes and other particles. We compared three lipids: a mono-NTA lipid (ca. 10 microM affinity) and two tris-NTA lipid derivatives (ca. 3 nM and 0.2 nM affinity) in their ability to retain two different his(6)-containing proteins on NTA-liposomes in the presence of serum or plasma and after intravenous injection in mice. At nanomolar affinities, the off-rate of a his(6)-ligand is sufficiently long so that his(6)-proteins attached to particle surfaces will remain with the particle for hours; thus, we hypothesized that the increased his(6) affinity of multivalent NTA-modified liposomes would retain his(6)-proteins longer both in vitro and in vivo. For each of the three lipids, we found a robust association and complete activity retention of two his(6)-modified proteins: a far red-fluorescent protein, monomeric Katushka (mKate), and a prodrug-converting enzyme, yeast cytosine deaminase (yCD). Proteins associated more tightly in vitro with tris-NTA liposomes than with mono-NTA liposomes in the presence of refiltered fetal calf serum and mouse plasma. Free yCD exchanged with previously associated mKate for tris-NTA binding sites on the liposome surface. This exchange was due to the exchange of the proteins for NTA occupancy and not due to the exchange of tris-NTA lipid out of the liposome. The amount of yCD on the surface was similar if the proteins were co-associated or if mKate was pre-associated. This exchange confirms that NTA associated proteins are in a dynamic state and can exchange with multihistidine proteins in the biological milieu. There was no difference in circulation time of the protein when it was intravenously administered by itself or attached to any of the NTA-modified liposomes because in vivo the protein was rapidly released from the NTA liposomes. Upon recovery from blood, liposomes containing tris-NTA accumulated a different plasma protein profile than control liposomes, suggesting that Ni-NTA specifically interacts with some plasma proteins. The reason for the rapid protein dissociation from the liposome in vivo is not clear; it could be due to displacement by endogenous histidine-containing proteins or to natural chelators that remove nickel from the NTA. Regardless of the cause, improvements in chelator or ligand design are needed before metal chelation will be capable of retaining histidine-modified proteins on NTA liposomes after in vivo administration.
Platt
Virginia
V
Joint Graduate Group in Bioengineering, University of California at San Francisco and Berkeley, San Francisco, California 94143, USA.
Huang
Zhaohua
Z
Cao
Limin
L
Tiffany
Matthew
M
Riviere
Kareen
K
Szoka
Francis C
FC
D000818:Animals; D006207:Half-Life; D006639:Histidine / Q000737:chemistry* / Q000378:metabolism; D008024:Ligands; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009571:Nitrilotriacetic Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D009942:Organometallic Compounds / Q000737:chemistry* / Q000378:metabolism; D011485:Protein Binding; D011506:Proteins / Q000737:chemistry / Q000378:metabolism*
D008024:Ligands; D008055:Lipids; D008081:Liposomes; D009942:Organometallic Compounds; D011506:Proteins; C088321:nickel nitrilotriacetic acid; D006639:Histidine; D009571:Nitrilotriacetic Acid
Chemistry. 2008;14(24):7186-92
18600817
Life Sci. 2003 May 23;73(1):93-102
12726890
Conf Proc IEEE Eng Med Biol Soc. 2005;2006:1036-8
17282364
Nat Methods. 2007 Sep;4(9):741-6
17721542
Biochim Biophys Acta. 1980 Oct 2;601(3):559-71
6251878
Amino Acids. 2006 Jun;30(4):351-67
16622600
Haemophilia. 2008 May;14(3):476-83
18393980
Bioconjug Chem. 2009 Mar 18;20(3):460-5
19239247
Biophys J. 1989 May;55(5):965-71
19431742
Anal Chem. 1996 Feb 1;68(3):490-7
8712358
J Chromatogr A. 2003 Feb 21;988(1):1-23
12647817
Biochim Biophys Acta. 2005 Oct 15;1716(2):104-16
16225839
Biochim Biophys Acta. 1991 Nov 18;1070(1):187-92
1751525
Bioconjug Chem. 2009 Aug 19;20(8):1667-72
19650657
Science. 2005 May 6;308(5723):857-60
15879217
Blood. 2006 Dec 1;108(12):3668-73
16888098
Bioconjug Chem. 1991 Nov-Dec;2(6):447-51
1805942
Biochemistry. 2005 Feb 15;44(6):1864-71
15697212
Biol Chem. 1998 Aug-Sep;379(8-9):1151-9
9792449
EMBO J. 1997 Mar 17;16(6):1199-213
9135137
Nat Biotechnol. 2004 Apr;22(4):440-4
15034592
Biochemistry. 1985 Mar 12;24(6):1496-501
3986189
Bioconjug Chem. 2006 Nov-Dec;17(6):1592-600
17105240
Chembiochem. 2009 Jan 5;10(1):55-62
19089881
Nat Struct Biol. 1999 Oct;6(10):926-31
10504726
J Am Chem Soc. 2005 Jul 27;127(29):10205-15
16028931
Nat Rev Drug Discov. 2008 Jan;7(1):21-39
18097458
Langmuir. 2007 May 22;23(11):6281-8
17444666
J Am Chem Soc. 2006 Feb 22;128(7):2365-72
16478192
Biochim Biophys Acta. 2002 Dec 23;1567(1-2):204-12
12488054
Annu Rev Biophys Biomol Struct. 2001;30:421-55
11441809
J Drug Target. 2006 Sep;14(8):576-82
17050123
Biochemistry. 1983 Mar 29;22(7):1621-30
6849872
J Mol Biol. 1999 May 21;288(5):1027-36
10329196
Small. 2008 Jul;4(7):970-81
18576284
BMC Immunol. 2006 Oct 02;7:24
17014727
J Drug Target. 2005 Aug;13(7):399-406
16308208
Chemistry. 2005 Sep 5;11(18):5249-59
15991207
J Control Release. 2009 Nov 3;139(3):229-38
19595724
BMC Biotechnol. 2002 May 10;2:9
12003642
Pharm Res. 2007 Feb;24(2):343-52
17180725
J Biosci Bioeng. 2005 Apr;99(4):423-8
16233812
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9014-8
7568063